Table 2.
Asthma characteristics of the SABINA III Gulf cluster cohort by investigator-classified asthma severity and practice type
|
All (N = 301) |
Primary care physicians (n = 135) | Respiratory specialists (n = 162) | |||||
|---|---|---|---|---|---|---|---|
| Mild asthma (n = 32) | Moderate-to-severe asthma (n = 103) |
All (n = 135) |
Mild asthma (n = 13) | Moderate-to-severe asthma (n = 149) |
All (n = 162) |
||
| Asthma duration, years | |||||||
| Mean (SD) | 14.8 (10.8) | 15.2 (11.4) | 14.4 (9.5) | 14.6 (10.0) | 10.2 (6.6) | 15.2 (11.8) | 14.8 (11.6) |
| Median (min, max) | 12.0 (1.0, 50.0) | 11.0 (1.0, 40.0) | 13.0 (1.0, 39.0) | 13.0 (1.0, 40.0) | 7.0 (2.0, 21.0) | 11.0 (1.0, 50.0) | 11.0 (1.0, 50.0) |
| Number of severe asthma exacerbations in the past 12 months | |||||||
| Mean (SD) | 0.9 (1.6) | 0.4 (1.0) | 0.9 (1.5) | 0.8 (1.4) | 0.6 (1.0) | 1.1 (1.8) | 1.1 (1.8) |
| Number of severe asthma exacerbations in the past 12 months by groups, n (%) | |||||||
| 0 | 175 (58.1) | 25 (78.1) | 63 (61.2) | 88 (65.2) | 9 (69.2) | 74 (49.7) | 83 (51.2) |
| 1 | 58 (19.3) | 3 (9.4) | 19 (18.4) | 22 (16.3) | 1 (7.7) | 35 (23.5) | 36 (22.2) |
| 2 | 31 (10.3) | 2 (6.2) | 6 (5.8) | 8 (5.9) | 2 (15.4) | 21 (14.1) | 23 (14.2) |
| 3 | 17 (5.6) | 1 (3.1) | 8 (7.8) | 9 (6.7) | 1 (7.7) | 7 (4.7) | 8 (4.9) |
| > 3 | 20 (6.6) | 1 (3.1) | 7 (6.8) | 8 (5.9) | 0 (0) | 12 (8.1) | 12 (7.4) |
| Level of asthma symptom control, n (%) | |||||||
| Well controlled | 147 (48.8) | 16 (50) | 42 (40.8) | 58 (43) | 11 (84.6) | 77 (51.7) | 88 (54.3) |
| Partly controlled | 78 (25.9) | 10 (31.2) | 30 (29.1) | 40 (29.6) | 0 (0) | 37 (24.8) | 37 (22.8) |
| Uncontrolled | 76 (25.2) | 6 (18.8) | 31 (30.1) | 37 (27.4) | 2 (15.4) | 35 (23.5) | 37 (22.8) |
| GINA treatment step, n (%)a | |||||||
| Step 1 | 19 (6.3) | 15 (46.9) | 0 (0) | 15 (11.1) | 3 (23.1) | 0 (0) | 3 (1.9) |
| Step 2 | 28 (9.3) | 17 (53.1) | 0 (0) | 17 (12.6) | 10 (76.9) | 0 (0) | 10 (6.2) |
| Step 3 | 125 (41.5) | 0 (0) | 56 (54.4) | 56 (41.5) | 0 (0) | 69 (46.3) | 69 (42.6) |
| Step 4 | 78 (25.9) | 0 (0) | 36 (35) | 36 (26.7) | 0 (0) | 40 (26.8) | 40 (24.7) |
| Step 5 | 51 (16.9) | 0 (0) | 11 (10.7) | 11 (8.1) | 0 (0) | 40 (26.8) | 40 (24.7) |
| Comorbidities, n (%) | |||||||
| None | 124 (41.2) | 11 (34.4) | 42 (40.8) | 53 (39.3) | 5 (38.5) | 63 (42.3) | 68 (42) |
| 1–2 | 137 (45.5) | 18 (56.2) | 45 (43.7) | 63 (46.7) | 8 (61.5) | 65 (43.6) | 73 (45.1) |
| 3–4 | 37 (12.3) | 3 (9.4) | 15 (14.6) | 18 (13.3) | 0 (0) | 19 (12.8) | 19 (11.7) |
| ≥ 5 | 3 (1) | 0 (0) | 1 (1) | 1 (0.7) | 0 (0) | 2 (1.3) | 2 (1.2) |
aBased on 2017 GINA recommendations
Prescriber type was not recorded for two patients each in mild asthma and moderate-to-severe asthma group
Abbreviations: GINA Global Initiative for Asthma, max maximum, min minimum, SABINA SABA use IN Asthma, SD standard deviation